Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.

Molecular cancer therapeutics - 1 Apr 2016

Phillips Andrew C, Boghaert Erwin R, Vaidya Kedar S, Mitten Michael J, Norvell Suzanne, Falls Hugh D, DeVries Peter J, Cheng Dong, Meulbroek Jonathan A, Buchanan Fritz G, McKay Laura M, Goodwin Neal C, Reilly Edward B

Abstract excerpt

Targeting tumor-overexpressed EGFR with an antibody-drug conjugate (ADC) is an attractive therapeutic strategy; however, normal tissue expression represents a significant toxicity risk. The anti-EGFR antibody ABT-806 targets a unique tumor-specific epitope and exhibits minimal reactivity to EGFR in normal tissue, suggesting its suitability for the development of an ADC. We describe the binding properties and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibody Affinity
Share to Cell Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Combined Modality Therapy

Share to Epitopes

Share to Glioblastoma

Share to Immunoconjugates

Share to Molecular Targeted Therapy

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 26846818
DOI: 10.1158/1535-7163.MCT-15-0901

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.PMID 26846818Read ↗

Depatuxizumab Mafodotin (ABT-414)-induced Glioblastoma Cell Death Requires EGFR Overexpression, but not EGFRY1068 Phosphorylation.Semantic proximity Read ↗

Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells.Semantic proximity Read ↗

Peptide-drug conjugates bearing an antimitotic Ahx-DA1 payload achieve potent antitumor activity in Her2-amplified and EGFR-positive KRAS-mutant cancers in vivo.Semantic proximity Read ↗

A Biparatopic Antibody-Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade.Semantic proximity Read ↗

Identification of antibody-drug conjugate payloads which are substrates of ATP-binding cassette drug efflux transportersSemantic proximity Read ↗

AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma.Semantic proximity Read ↗

Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial Transition Factor (MET) Bispecific Antibody, Designed to Enable Multiple Mechanisms of Action and Broad Clinical Applications.Semantic proximity Read ↗

Expanding the repertoire of Antibody Drug Conjugate (ADC) targets with improved tumor selectivity and range of potent payloads through in-silico analysis.Semantic proximity Read ↗

The emerging role of antibody-drug conjugates in EGFR-mutant non-small cell lung cancer with acquired resistance to third-generation EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

A New Class of Antibody–Drug Conjugates with Potent DNA Alkylating ActivitySemantic proximity Read ↗

Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer.Semantic proximity Read ↗

Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.